Lipidation, PEGylation and Cyclization: How Peptides Are Modified

Quick overview

A natural peptide hormone is usually a poor medicine as it stands. Enzymes cut it up and the kidneys clear it within minutes. Chemists therefore modify the molecule. Three common ideas are lipidation (attaching a fatty acid), PEGylation (attaching polyethylene glycol, a long water-loving chain) and cyclization (closing part of the chain into a ring). This page explains the ideas using regulator labels and reviews. It is science education, not advice about any product.

Evidence labels used here: approved medicine where a US label is the source, and preclinical where only laboratory work is described.

The problem being solved

One review explains that short plasma half-lives are commonly due to fast renal clearance and enzyme degradation in the blood, liver and kidney. [1] A related review of long-acting peptide design says short half-life and poor physical and chemical stability have limited peptide use. [2]

Lipidation: borrowing albumin

Albumin is a protein that circulates in blood. In lipidation, a fatty acid chain (often with a linker) lets the peptide bind albumin reversibly, which slows its clearance. A review of liraglutide and semaglutide development says reversible albumin binding was used for the systemic protraction of both drugs. [3]

The US label for Ozempic (semaglutide, Novo Nordisk, DailyMed label published 2026-06-10) states the principal protraction mechanism is albumin binding, facilitated by modifying the lysine at position 26 with a hydrophilic spacer and a C18 fatty di-acid. It adds that position 8 is modified to protect against the enzyme DPP-4. [4] The label gives the elimination half-life as approximately 1 week. [4] For the natural hormone this drug is modeled on, see GLP-1 and GIP Biology.

Important distinction: semaglutide is an analogue with an engineered side chain. It is not the natural hormone, and a lipidated molecule is a different substance from the unmodified peptide in a different compound's study.

PEGylation: a polymer shield

Attaching polyethylene glycol increases size and can shield a molecule from enzymes and kidney filtration. One review found PEG conjugation to be an effective approach to increasing serum half-life. [5] An earlier review of half-life strategies reported a PEG conjugate of interferon alpha-2b with a 330-fold longer plasma half-life than the native protein. [1] That example is a protein, not a short peptide, and the size of the gain varies by molecule.

PEGylation has trade-offs. The same review links PEGylated products to immune reactions, including anti-PEG antibodies and complement activation causing hypersensitivity, while noting that claims about antibodies are hampered by a lack of standardized, validated assays. [5] It reviews PEGylated therapeutics in general, so the details differ by product. See Immunogenicity of Peptide Medicines.

Cyclization: closing the ring

Linear peptides are floppy and easy for enzymes to grab. Making a ring constrains the shape. A 2018 review says macrocyclization of linear peptides can be an effective strategy to improve membrane permeability, proteolytic stability and oral bioavailability, while also saying that developing orally bioavailable peptide-based drugs remains challenging. [6] A 2024 review notes that cyclic peptides are abundant in nature and that on average about one cyclic peptide drug has been approved per year. [7]

A classic example: the review of half-life strategies reports that octreotide, a shortened somatostatin derivative in which L-amino acids were replaced by D-amino acids, had a plasma half-life of 1.5 hours compared with only a few minutes for somatostatin. [1] Replacing amino acids is a related tactic, separate from ring formation, and the review does not credit one change alone.

The difference at a glance

What these modifications do not mean

• A longer half-life is not the same as a better medicine. See Pharmacokinetics vs Clinical Effectiveness.
• Naming a modification on a product label or website does not establish identity. Some marketed research-peptide names have no verified link to a published compound; see Research Peptide Naming and Identity Problems.
• Proper evidence not found: I looked in PubMed reviews and the semaglutide label for a head-to-head comparison showing one modification is generally superior, and none was available.

Related guides

• Natural, Synthetic and Modified Peptides
• Depot and Extended-Release Formulations